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LIVER HOMOTRANSPLANTATION 
Thomas E. Starz/, M.D., Ph.D., and Charles W. Putnam, M.D. 
Treatment of terminal liver disease by transplanta-
tion was founded on the encouragement and knowl-
edge provided by the steadily improving experience in 
renal transplantation.n . 27 However, the liver is a far 
more complicated organ, and its malfunction leads to 
vastly more complex physiologic derangements. Liver 
patients are. further handicapped, as __ are heart pa-
tients, by the lack of a satisfactory means of artificial 
support comparable to renal dialysis that could take 
over the organ's compromised functions during the 
wait for a suitable donor, or over the critical immedi-
ate postoperative period. The transplanted liver must 
function efficiently practically from the moment of 
anastomosis or the patient is lost. 
Despite these and other difficulties, there has been 
enough progress in the laboratory and clinic to state 
that liver transplantation is now a feasible and legiti-
mate, although imperfect, form of therapy, and one 
that may in certain cases be considered the treatment 
of choice. Human survivals up to 6 years have been 
achieved. A great deal has been and is being learned 
at a pace that suggests that liver transplants will soon 
have at least as much chance to succeed as kidney 
grafts now have. 
KINDS OF LIVER TRANSPLANTATI.oN 
There are two general approaches to transplanta-
tion of the liver. With the first method, the host liver 
is removed and replaced with a homograft (orthotopic 
homotransplantation). The alternative technique is 
the insertion of an extra liver (auxiliary homotrans-
plantation) at an ectopic site. Both procedures were 
developed in dogs and later studied in other species 
induding rats, pigs, monkeys, and humans. The most 
encouraging results have been with orthotopic trans-
plantation, for which reason most of this chapter will 
be concerned primarily with this replacement opera-
tion. However, in a special section near the end of the 
chapter, auxiliary hepatic transplantation also will be 
briefly considered. 
IMMUNOLOGIC CONSIDERATIONS 
Is the Liver a Privileged Graft? 
When research in liver transplantation was in its 
early stages, it was suggested by Cannon5 that if the 
liver played a significant role in graft rejection, hepa-
tic homografts might enjoy a better fate than other 
transplants because presumably the grafted liver 
would not participate in its own repudiation. The case 
for this rather mystical view even seemed strength-
ened by certain experiences with laboratory animals. 
When immunosuppression in canine recipients was 
stopped after 4 months, a surprising number of ani. 
mals continued to thrive either with no signs of rejec-
tion or with rejection episodes that waxed and waned 
remittently.so.!1 One such dog lived in our laboratory 
with stable liver function for 11 years and 8 months 
after transplant. This phenomenon of "graft accep-
tance" had been noted in dogs with renal trans-' 
plants,n. t7 but less frequently. 
If the liver thus seemed to be an immunologically 
favored organ for transplantation in dogs, its status in 
pigs as observed by Garnier,' Terblanche,2' Calne4 and 
in our o~ laboratory21 was even more noteworthy. In 
some experiments with pigs not treated with immuno-
suppressive agents, identifiable homograft rejection 
did not occur. In other experiments, rejection was 
indolent and spontaneously reversed. These surprising 
results occurred in only a minority of animals. Never-
theless, they had to be attributed to some special priv-
ilege of the liver, since porcine skinll and kidney 
graftgC were regularly rejected in the usual way. 
These observations in both dogs and pigs (and now 
in other animals) invited certain hypotheses in addi· 
tion to the one stated above that the new liver helped 
create an internal milieu favorable to itself. Other 
possibilitiegZ7 were that the liver was inherently less 
antigenic than other organs, that its relatively great 
antigenic mass was a beneficial factor, that its enor-
mous regenerative capacity made it less susceptible 
than other tissues to the effects of chronic rejection, or, 
in the view of CaIne,S that it possessed or released 
some special factor promoting the induction of specific 
immunologic tolerance. 
Whatever the explanation, overstatement of the 
case for the liver's privileged status could lead to erro-
neous conclusions about the practical requirements for 
immunosuppressive therapy following hepatic trans-
plantation in man. At a research level, another danger 
could stem from the notion that hepatic transplanta-
tion, especially in the ):Jig, is somehow qualitatively 
unique. The fallacy of such a contention is obvious 
from the fact that even in the "easy" pig model, the 
majority of untreated liver recipients died from acute 
rejection.!7 In dogs and humans, control of hepatic 
rejection may be difficult or impossible in spite of very 
heavy immunosuppressive therapy.2o.27 
Re/ecUon Reversal 
Instead of being unique, it is probable that liver 
homografts vary from other organs only by degree in 
the host immunologic response they evoke in all 
species including the pig. In this context, two key ob-
servations initially made with kidneysJ7· II have been 
extended to the liver,20. S7 and there is little doubt that 
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they apply to other tissues as well. The first is the 
reversibility of rejection. In patients, reversal usually 
requires intensification of treatment, but it has some-
times been noted without any change in the pre-exist-
ing therapy, suggesting that such recoveries had an 
element of spontaneity. As mentioned earlier, "sponta-
neous remission" of rejection in the absence of all ther-
apy has been seen both in dogs and in pigs, particu-
larly the latter. The events with the liver in all three 
species are undoubtedly expressions of the same phe-
nomenon, differing only quantitatively. 
Graft Acceptance 
The second observation of overriding practical and 
theoretical interest concerns what has already been 
referred to as "~aft acceptance." In many of the 
human kidney recipients. treated almost a decade 
ago,l1· 22. 27 it was shown that a melting away of host 
resistance to the homograft occurred surprisingly 
early after transplantation, often following an acute 
rejection crisis. This was manifested by eventual de-
clines in the doses of immunosuppressive agents nec-
essary to retain stable graft function. In many pa-
tients, .the level of chronic immunosuppression has 
proved to be less than that which at the outset failed 
to prevent the onset of a severe rejection. 
All treatment has been stopped without subsequent 
rejection by some of these human renal recipients 
whom we have now followed for many years, but such 
a drastic final step is known to be exceptionally dan-
gerous. However, as described earlier, therapy has 
been successfully discontinued in dogs after kidney 
transplantation and even more consistently after liver 
replacement, indicating that graft acceptance may 
become very complete. In pigs, the barrier of natural 
host resistance is apparently low enough that the 
cycle of hepatic graft acceptance can be completed 
without any immunosuppression at all. Viewed in this 
way, the curious pig liver experiments become only a 
special example of, rather than an exception to, a gen-
eral principle of transplantation. Perper and his as-
sociatesl3 and subsequently other authors have pro-
vided evidence to support both this concept and the 
original idea that there is a slight but limited biologic 
advantage in transplanting the liver versus the kid-
ney. Perper showed that a 3-day course of hetero-
logous antilymphocyte globulin (ALG) treatment or 
other short-term therapeutic maneuvers in pigs per-
mitted long-term acceptance of kidneys in precisely 
the same way as occurs with the liver in the absence 
of all iatrogenic intervention. 
Explanations for Graft Acceptance 
It is indisputable that some element of acceptance of 
various kinds of grafts occurs often in humans under 
the appropriate conditions of immunosuppression and 
that the degree to which this develops is a prime de-
terminant of the long-term prognosis. Unfortunately, 
the reason for the change in the host-graft relation-
ship is not known. More than one immunologic path-
way may be involved. 
Immunologic Tolerance. Schwartz and Dameshek16 ' 
first suggested the possibility that the continuous 
presence of a transplanted organ in a host being 
treated with immunosuppressive therapy could lead to 
D~a selective loss of responsiveness to antigens. The 
suggestion is that specific lymphocyte clones, induced 
to replicate by the graft antigens, are thereby ren-
dered more vulnerabfe to the killing effect of immuno-
suppressive agents than the rest of the lymphocyte 
population (Fig. 1). Inasmuch as the maintenance of 
such activated cell lines appears to be thymus-depen-
dent even in adult life, at least in some experimental 
animals, it is reasonable to be curious about the effect 
of thymectomy as an adjuvant immunosuppressive 
measure. The results of thymectomy in a series of our 
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FIgure 1. Hypothetical mechanims by which 
nonspecific immunosuppression may lead toselec-
tive abrogation of the host immune response. Spe-
Cial susceptibility to these agents of a fraction of the 
lymphoid population could lead to exhaustion of a 
clone. and hence. tolerance. Since maintenance of 
such cell lines even in adult life is apparently thy-
mic-dependent in experimental animals. thymec-
tomy would be expected to aid the process; this ap-
pears to be true in rodents. but such an effect of 
thymus removal has not been proved In dogs or 
humans (see discussion in lext). A possible protec-
tive role of Immunoglobulins elaborated by the 
replicating cells Is also shown. 
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human renal transplants were inconclusive.u While 
the patients with thymic excision did not have better 
survival or superior renal function, there were fewer 
and less severe histopathologic abnormalities when 
their grafts were examined long after transplantation. 
The concept of specific, differential tolerance 
through "clone stripping" can partly explain the char-
acteristic cycle of rejection and reversal occurring 
after whole-organ transplantation both in treated ani-
mals and man and in the weak and self-resolving 
crises in the untreated pig. Moreover, it is consistent 
with the fact that a wide variety of agents that are 
capable of general immunologic crippling can also 
provide specificity of action under the stipulated condi-
tions of immunosuppressive treatment during pre-
sence of the antigen. 
To date, few investigations have been performed in-
human recipients of chronically functioning renal ho-
mografts to establish the presence or absence of classic 
immunologic tolerance to their donor tissue. It would 
be interesting to know if skin from these donors would 
be accepted. One of the reasons why such a test has 
not been carried out in patients is the potential risk of 
precipitating an immune reaction that could damage 
the graft.1! Of course, viable donor tissue is not avail-
able for such an experinent in liver recipients even if 
this were a desirable undertaking. 
Amos and Bach2 have provided evidence that at 
least some kidney recipients develop true tolerance to 
their donors. They performed mixed lymphocyte cul-
tures with peripheral blood from a number of our 
renal recipients and their donors 2 to 4 years after 
transplantation. In some cases, the recipient lympho-
cytes no longer developed blast transformation when 
exposed to killed donor white cells, although they 
reacted vigorously to third-party cells. However, in 
other cases recipient lymphocytes retained their reac-
tivity to donor cells. In experiments, dogs with tol-
erated kidneys may promptly reject skin or kidney 
grafts from the original donor. 
Enhancement. These ambivalent findings do not 
disprove tolerance through "clone stripping" so much 
as they suggest that _ at least another mechanism of 
graft acceptance may be involved. One such mecha-
nism,termed "enhancement," has been envisioned as 
a process in which immunoglobulins synthesized by 
the activated lymphoid tissues circulate to the target 
tissue and coat it or protect it in some way that is not 
yet understood (see Fig. 1). Antigraft antibodies, selec-
tively capable of being absorbed by the nucleated cells 
of the original donor, have been detected in patients 
carrying well-tolerated renal transplants. Extensive 
immunoglobulin deposition has been demonstrated by 
immunofluorescence techniques in long-functioning 
kidney homografts,1' but this latter finding usually 
has an adverse connotation rather than a favorable 
one. 
The two foregoing mechanisms of graft acceptance 
by tolerance induction and enhancement are not mu-
tually exclusive. The Seattle transplantation group 
headed by Marchioro, using the techniques developed 
by the Hellstroms, has demonstrated changing host-
graft relationships in kidney recipients that are con-
sistent with a multifactorial graft-acceptance hypothe-
sis. 14 
TISSUE TYPING 
Another way by which clinical results might be 
improved would be effective donor-recipient matching 
of histocompatibility (HLA) antigens as discussed else-
where in this chapter. Unfortunately, the state of our 
knowledge about human histocompatibility systems is 
still primitive. While a good match between siblings 
appears to provide a more favorable prognosis after 
renal transplantation than a poor match, our experi. 
ence with unrelated subjects provides no such correla-
tionU and has led us for the moment to ignore the 
question of HLA matching altogether in cadaveric 
cases. In liver transplantation, in which nonrelated 
cadaveric sources must be utilized exclusively, we 
have had some excellent results with poor histocompa-
tibility matches and some discouraging results despite 
close matches.le• 27 Not only has a correlation with tis-
sue typing been absent with regard to clinical out-
come, but no connection at all has been found between 
the quality of the match and the appearance of the 
hepatic homograft at subsequent histologic exarnina-
tion.!7 Until the discrimination of the matching 
methods in nonrelated cases is improved, it is difficult 
to justify denying a patient an available organ solely 
on the basis of poor serologic histocompatibility. Nor 
do we even use most favorable matching as an in-
strument of selection among candidates for transplan-
tation. At the present time, a more valid criterion may 
be who has the most pressing need. 
There is even reason to believe that screening proce-
dures for preformed antigraft antibodies are not as 
critical in liver cases as with the kidney. I. Preformed 
anti-red cell isoagglutinins that react against donor 
tissues and cytotoxins that can be detected by their 
lysis of donor lymphocytes immediately destroy many 
. renal homografts that are transplanted in violation of 
such positive crossmatches.tT The liver is very resis-
tant to this so-called hyperacute rejection.28 In our 
series, 3 liver transplantations were carried out in 
spite of red blood group incompatibility and.3 more 
were performed in confrontation of cytotoxic antibo-
dies. There were no unequivocal hyperacute rejections. 
THE PROCUREMENT OF ORGANS 
In contrast to typing, the procurement of a fresh, 
functioning, nonischemic liver ~of paramount advan-
tage and provides the strongest correlation with suc-
cess or failure. 
The Source of Donors 
In discussing homograft quality, the technical de-
tails of organ preservation become interwoven with, or 
even distinctly secondary to, ethical considerations 
about the conditions for the pronouncement of donor 
death and problems of cooperation by the medical and 
lay community. Unquestionably, one of the most im-
portant advances that have been made in transplanta-
tion has been social in nature, consisting of acceptance . 
by the public of the concept of cadaveric organ remov-
al. In turn, this was made possible by a willingness of 
many members of the medical profession to identify 
potential donors, to approach family members at a 
-----~--K------D~-
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time of their bereavement, or to indicate in other ways 
their belief in the propriety of these efforts. By avoid-
ing the glare oflay publicity, this can be and has been 
done impersonally and with restraint in many areas 
without exaggeration and without infringing on the 
personal right to privacy of the individuals involved. 
Pronouncement of Death 
After the donor has been identified and made avail-
able, an effort is made to maintain good liver per-
fusion up to the last possible moment in order to 
minimize the ischemic damage that even a short un-
perfused period may wreak under normothermic con-
ditions. The extraordinary resuscitative efforts 
required in the donor to prevent circulatory depression 
in the face of a hopel~ prognosis usually require ex-
planation to relatives. 
Ultimately, a final decision to discontinue suppor-
tive measures may be made after all is in readiness to 
proceed with the recipient. During the first years of 
liver transplantation at the University of Colorado, a 
considerable physiologic penalty was accepted because 
of criteria that required both brain death and cessa-
tion of heartbeat before commencing with organ remov-
al. The price of this insistence was the loss of critical 
time, and variable ischemic damage both during the 
agonal stages of circulatory failure and in the minutes 
after cardiac arrest.27 __ --
The reason for accepting these conditions was the 
fear that the quality of terminal care for the donor 
might be compromised by the pronouncement of death 
in the presence of a heartbeat. In 1968 our criteria 
were liberalized in accordance with the concept of irre-
FIgure 2. Technique of extracorporeal perfu-
sion with a heart-lung machine. Catheters are in-
serted via the femoral vessels into the aorta and 
vena cava as soon as possible after death. The ex-
tracorporeal circuit Is primed with a glucose or 
electrolyte solution to which procaine and heparin 
are added. The cadaver is thus anticoagulated with 
the first surge of the pump. Temperature control 
I, provided by the heat exchanger. Cross-clamping 
the thoracic aorta limits perfusion to the lower 
part of the body. 
versible brain injury as it was first outlined and 
applied at the University of Louvain, Belgium, by 
Alexandre,! and later defended by the Harvard ad hoc 
committee.1 Experience since then has convinced us 
that anxieties about terminal care were unfounded. 
Acceptance of the brain death concept alleviated one 
of the most serious problems in liver transplantation, 
for it virtually eliminated the interval of normother-
mic ischemic injury and often permitted the organ to 
be taken in the presence of an intact and effective 
circulation. 
Preservation Techniques 
The subsequent preservation of the liver is also of 
vital importance and has been accomplished by one or 
more preservation modalities, depending on circum-
stances, and always including organ hypothermia.1T 
With the advantages conferred by the acceptance of 
brain death, it is often possible to maintain a natu-
rally perfused liver in situ practically up to the mo-
ment of its excision. After removal, quick cooling may 
be accomplished by running a chilled electrolyte solu-
tion through the portal vein, thus lowering the donor 
organ temperature to about 10 or 15° C., which is suf-
ficient for adequate preservation during the hour or so 
required for the vascular anastomoses in the recipient. 
In the event of a heart standstill before the recipient is 
ready, it is possible to employ the procedure used 
before 1968, when cardiac arrest was required before 
proceeding; by means of a heart-lung machine, circu-
lation in the cadaver is reinstituted in combination 
with cooling (Fig. 2). Complicated preservation devices 
are no longer used. 
, 
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SURGICAL TECHNIQUES OF ORTHOTOPIC or obstruction may also be complicated by the presence ,". 
TRANSPLANTATION of biliary tract anomalies, and the surgeon must be 
prepared to tailor his procedure to the individual case. • ", 
Species Differences Choice of Biliary Drainage. In several of our first re. 
The procedure of liver replacement was first accom- cipients who did not have biliary atresia, bile duct 
plished in dogs. The transition from animal expe~i- reconstruction was with choledochocholedochostomy 
mentation to clinical application required some major over aT-tube stent (Fig. 3D). The method lost favor 
technical adjustments and in at least one important because of a high incidence of biliary fistula, and 
and unexpected way demonstrated the need to be alert cholecystoduodenostomy after ligation of the common 
to the special requirements of human physiology. duct (Fig. 3A) became our first choice for a number of 
With removal of the host liver it is necessary to cross- years. However, since November, 1973, the preferred ,', 
clamp temporarily the great veins draining the intes- technique has been cholecystojejunostomy with a 
tines (portal vein) and the lower half of the body (infe- Roux-en-Y loop (Fig. 3B), thus removing the homo-
rior vena cava). If provision is not made for decom- graft from the mainstream of the gastrointestinal 
pression of the distal venous pools during the tract and draining it through a defunctionalized je. 
anhepatic phase, dogs either die of shock on the junallimb. Alternatively, Roux-en-Y choledochojejun_ 
operating table or expire at a later time because of it- ostomy (Fig. 3C) has been used for recently treated pa. 
reparable damage to the mesenteric capillary bed. It tients. In a number of cases it has been necessary to 
was assumed that the same precaution would be nec- convert from cholecystojejunostomy to choledochoje-
essary in humans and this was accomplished in the junostomy (Fig. 3B and C) because of delayed obstruc-
first five human recipients by plastic bypasses from tion at the cystic duct. It, 18 
the splenic or femoral vein or both to the external jug- Bile Duct Anomalies. Ligation of the transplant com-
ular veins. There was a dismaying incidence of pulmo- mon duct in Conjunction with cholecystoduodenostomy 
nary emboli, which caused or contributed to the may be dangerous if anomalies are not recognized. 
death of three of the first five recipients. It was sus- Communication between the cystic and common ducts 
peeted either that the clots originated within the may not always be at the point of their juncture (Fig, 
bypasses and were actually carried to the lungs during 4). In one patient the ducts were externally fused but 
the operation or that they formed a short time later at separated by an internal septum; in 2 others the 
or near the site 'where the femoral catheter had been homograft cystic duct passed behind the common duct 
inserted. and descended for almost 2 inches as one compartment 
The omission of the venous decompression procedure of a double-barreled lumen. In all 3 cases, biliary 
in later patients did not produce any serious or long- drainage was inadvertently obstructed when the com-
lasting circulatory effects, including hypotension. AI- mon duct ligature closed both parallel passages, a 
though a slight duskiness of the intestine developed in technical error that subsequent surgery failed to cor-
some recipients, it immediately disappeared when rect and that proved fatal. 
blood flow was restored through the reconstructed ve- Some of the vascular and ductal anomalies could 
nous channels. One can explain the ease with which - nave been diagnosed preoperatively, resulting either 
portal and vena caval cross-clamping was tolerated by in better planning for surgery or a decision not to 
man's inherently richer network of potential collateral operate at all. These earlier cases did not, however, 
channels for the return of blood to the right heart, and have the benefits of the extensive arteriography and 
by the presumed additional increase in their size and cholangiography that are now used routinely in the 
ramifications in consequence of the underlying liver donor and sometimes in the recipient as well. 
disease.27 Venous decompression with bypasses has 
not been used in any recent case. 
Vascular Anomalies 
In planning a liver transplantation, the surgeon 
must be prepared for a high incidence of anatomic 
variations in either the graft or host structures.17 
These have been encountered in almost 40 per cent of 
our cases. Multiple arteries have been the most 
frequent anomalies. When these have been in the re-
cipient, most commonly the graft celiac axis has been 
connected to the host aorta. When the multiplicity has 
been of the transplant vessels, multiple arterial anas-
tomoses or other variant procedures have been used. 
There is no question that the need to improvise in 
these situations imposes an extra risk, particularly in 
very young recipients whose arteries are quite small 
and thin-walled even under the best technical circum-
stances. 
Bile Duct Problems 
The problems of obtaining adequate bile drainage 
and avoiding technical errors that may lead to leakage 
Hemorrhage 
Other problems during and after operation may be 
caused by derangements in the coagulation mecha-
nism that may result in eith~ hemorrhage or throm-
bosis.27 As one would expect, acute bleeding .can be 
particularly troublesome during the actual liver trans-
plantation. The very nature of the underlying hepatic 
pathologic process produces portal hypertension in 
nearly every patient, and the nature of the operation 
tends to exaggerate it. The usual consequence is me-
chanical bleeding that can rapidly assume nightmare 
proportions during the procedure. Many of the normal 
coagulation factors that might help control hemor-
rhage are dependent on the liver and are therefore 
defective in the diseased recipient. These coagulation 
factors may be even more deficient during the anhepa-
tic phase, or subsequently they may be of dubious 
quality, depending on the state of preservation of the 
homograft, on how much ischemia it has suffered, and 
DK~ 
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FIgure 3. Techniques"" biliary duct recon-
struction used for most liver transplant recipi-
ents. A, Choleeystoduodenostomy. 8, Cholecy-
stojejunostomy. C, Choledochojejunostomy after 
removal of gallbladder. D, Choledochodochos-
tomy. Note that T-tube is placed if possible in 
recipient common duct. (From Starzl, T. E., et al.: 
Surg. Gynecol. Obste!., 142:487, 1976.) 
Homograft liver 
~~~~I1jg duodenostomy 
c 
Right a left 
hepafic duct 
FIgure 4. The anatomic basis for a technical error which cost the 
life of a patient. Distal ligation of the double-barreled extrahepatic 
duct system resulted In total biliary obstruction. 
T-tube in recipient 
common duct 
o 
on how much immediate fun'ctional capability it has 
retained. 
When hemorrhage occurs, the surgeon's challenge is 
to use any and all available hemostatic tactics-ligat-
ing, suturing, cauterizing-until the revascularized 
homograft can participate in what is hoped will be ap-
propriate coagulation function. With our earlier pa-
tients, whose homografts were generally of less than 
optimal quality for the reasons stated earlier, an at-
tempt was made to treat bleeding problems by ad-
ministering thrombogenic agents. However, hyper-
coagulability was caused in some instances. The 
unacceptable incidence of pulmonary embolism in 
these patients led us to abandon this approach. 
In retrospect, it is possible that the coagulability in-
duced by exogenous thrombogenic agents might be 
prohibitively additive to the clotting brought about by 
the homograft which, when it begins to function, may 
overreact. Indeed, the better the condition of the 
transplant, the greater the risk of unwanted coagula-
tion. Alr.nost every series of liver transplants, includ-
ing our own, has at least one example of thrombosis of 
I 
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the hepatic arterial circulation to which a rebound 
phenomenon may have contributed. The use of anti-
coagulants to forestall this emergency is dangerous. 
Documented intravascular clotting during the opera-
tion would be an indication for heparin, but such proof 
is hard to obtain. Moreover, heparinization is a 
double-edged maneuver; depressed clotting can have 
devastating effects on patients submitted to such 
major trauma and with so many potential bleeding 
sites. 
In general, it is now considered best to avoid ia-
trogenic manipulation of the clotting process with ei-
ther thrombogenic or anticoagulant agents. Instead, 
our current approach is to leave correction of coagula-
tion abnormalities to natural processes, intervening 
only under special circumstances and for very specific 
indications. 
Anesthesia 
During operation, there are other metabolic abnor-
malities than those concerned with coagulation. These 
contribute to the complexity of anesthetic manage-
ment. Not only is the procedure long and difficult, but 
even more important, it is an operation on the pri-
mary organ involved in the metabolism and detox-
ification of most common anesthetics. At any point 
during the operation, the liver is either inherently im-
paired, absent, or untried in its new setting. Hence, 
the task of the anesthesiologist is to administer cor-
rectly drugs that, first, are not hepatotoxic and, sec-
ond, do not depend primarily on the liver for their deg-
radation. In our cases, reliance has been placed 
mainly on combinations of volatile agents in nonexplo-
sive concentrations. Such management permits use of 
the electrocautery, gives flexibility in lightening or 
deepening anesthesia, and allows anesthesia -to be 
abruptly stopped if required by changing physiologic 
circumstances. %7 
Other Operative Problems 
The foregoing are some selected difficulties asso-
ciated with liver transplantation. There is a long list 
of other technical pitfalls: adrenal venous infarction, 
air embolism, and crushing of the right phrenic nerve 
by too high a clamp on the upper vena caval cuff, to 
mention but a few. The reader interested in a more de-
tailed discussion of these and other surgical problems 
is referred to more detailed pUblications. It. 26. 27 These 
technical matters have played a major role in the mor-
tality encountered in our first cases. Even though 
deaths from such causes are theoretically avoidable, 
technical misadventures still constitute the leading 
cause of failure, as has been very well documented in 
our exhaustive study of the first 93 consecutive 
cases.-
IMMUNOSUPPRESSION 
The immunosuppressive therapy in liver transplan-
tation has borrowed heavily from the experience 
gained with human renal transplants. Two general 
treatment programs were evolved with the 
kidney model and then applied to the liver recipienta.' 
Double Drug Therapy 
The first protocol, which was used from 1962 to 1966 
for all organ recipients at the University of . 
consisted of "double drug" treatment with 
prine and the synthetic adrenal cortical steroid, 
nisone,11 Evolution of the use of these two agent.· 
together, appreciation of their marked synergism, and 
demonstration that rejection could be readily revel'8ecl 
by increasing the steroid doses were among the 
vances that made clinical transplantation 
and that introduced what is known as the 
of this field. But in spite of fair results with renal 
transplantation, the double drug therapy either did 
not prevent rejection of hepatic homografts or else it 
proved too toxic to permit host survival. Six patient. 
treated with liver transplantation from 1963 to 1965 
died in a month or less. 
Triple Drug Therapy Including ALG 
In 1966, heterologous antilymphocyte serum (ALG) .. 
was introduced clinically at our center as a third im-
munosuppressive agent, added to the drugs mentioned . 
above.24 • 27 Since then, this triple drug therapy baa 
been given to all our renal, hepatic, and cardiac recipi. 
ents, even though not all transplant surgeons concede· 
the need for ALG. 
Almost all of our human liver recipients who 
achieved chronic survival were treated with the com-
bination of azathioprine, prednisone, and intramuscu. 
lar ALG. In the event of a rejection episode, it is the 
steroid component that has proved to be the agent 
most amenable to quick adjustment of dosage accord-
ing to need. In the event that hepatotoxicity of azathi-
oprine is suspected, we have been free to substitute ' 
the alkylating agent, cyclophosphamide, which haa 
immunosuppressive qualities equivalent to azathio-
prine.28 
Penalties of Immunosuppression 
Some of the hypotheses of the actions of these im-
munosuppressive drugs have been discussed else-
where27 and reviewed earlier in this chapter. Suffice it 
to say, as was emphasized at the outset of this chapter, 
the method by which these agents are used in conjune> 
tion with the actual transplantation may conspire to 
permit selective abrogation of tile host rejection re-
sponse. If this were not true, there would be little hope 
of rehabilitating patients and returning them to life in 
an unrestricted environment, since each of the indi-
vidual agents can cause general immunologic cri~ 
pling more or less in proportion to the dose used. 
Risks with All Organs. The most obvious penalty of a 
depressed immune system is heightened susceptibility 
to infectionY' 27 However, it has also become obvious 
that chronically immunosuppressed patients have an 
increased vulnerability to de novo malignancies.1M' 
In our own series of chronic survivors after renal 
transplantation, more than 5 per cent have developed 
either mesenchymal or epithelial malignant tumors. 
Almost all other major transplantation centers have 
recorded this complication, which is presumably due 
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to failure of the depressed immunologic surveillance 
mechanism to identify the tumor tissues as alien and 
to eliminate them or restrict their growth. 
Extra Risks for liver Recipients. In addition to the 
foregoing general liabilities of immunosuppression, 
there are some special risks for the liver candidate. 
One is the fact that hepatic injury in all kinds of organ 
recipients has commonly been produced by the agents, 
individually or in combination, of the therapeutic regi-
menP In some instances, virus hepatitis, apparently 
made chronic by the partial immunologic invalidism 
of the host, has been a plausible explanation. In 
others, hepatotoxicity of the drugs was probably re-
sponsible. With liver malfunction, dose control of some 
of the agents may ~come difficult, since the liver par-
ticipates in their pathways of action or degradation. 
These hepatic factors are obviously important in any 
situation requiring immunosuppression, but they have 
heightened significance for a traumatized liver trans-
planted to a new and hostile environment. 
It was mentioned in the preceding section that infec-
tion was a major risk to any immunosuppressed pa-
tient. In the liver recipient, postoperative sepsis of the 
Figure 5. An explanation of the predisposition of the liver to bac-
terial sepsis. Presumably the invading microorganisms enter via the 
portal vein or through the reconstructed biliary tract. (From Staizl. 
T. E .• et al.: Ann. Surg .. 168:392. 1968.) 
graft itself has proved to be a special problem, without 
doubt partly because of the anatomic location of the 
orthotopically placed organ, interposed between the 
intestinal tract and the heart. Bacteria from the 
bowel, particularly of the gram-negative variety, can 
be brought into contact with the transplanted liver via 
the intestinal veins draining into the portal vein or, 
far more importantly, by retrograde spread up the 
duct system after passage through the biliary anas-
tomosis (Fig. 5). In either event, the presence of non-
viable hepatic tissue provides a perfect medium for 
bacterial growth. Eventually, partial gangrene of the 
transplant can result, with characteristic nonvisualiz-
ing areas on the liver scans (Fig. 6), gram-negative 
bacteremia, and all the findings of generalized sepsis. 
Avoidance of Homograft Sepsis. Early in our clinical 
series, the above findings of graft and systemic infec-
tion led us to consider the essential problem to be one 
of bacterial invasion and thus prompted reductions of 
immunosuppression. Such decisions were tragically 
incorrect and were followed by necrosis and infection 
of large parenchymal areas. Experience soon taught 
that ischemia of portions of the liver was the initiat-
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Figure 6. Postoperative technetium scans of the liver in a 13-month-old infant whose indication for orthotopic transplantation was biliary 
atresia. 2 days: The small homograft is normal. 10 days: An increase in size is evident although the general configuration of the organ is stili 
normal. 20 days: No further change is noted. 25 days: The examination was conducted as an emergency when gram-negative septicemia devel-
oped and v>Jry high increases in thetransaminases appeared. Areas of decreased isotope uptake are obvious in the right lobe and the central part 
of the liver. 27 days: A striking extension of the process can be seen less than 48 hours later. A debridement procedure was carried out the same 
evening. 31 days: Four days after d6bridement the radiographic appearance was improved. 
ing event, and that the basis for the ischemia was 
rejection.27 Consequently, immunosuppression should 
ordinarily be increased rather than reduced if this 
complication is thought to be impending. When this 
was done by giving substantially higher doses of pred-
nisone (as noted, the only highly dose-maneuverable 
component of the immunosuppressive triad), the in-
cidence of regional hepatic gangrene fell to nearly 
zero. It should be added that our prophylactic treat-
ment protocol includes heavy antibiotic treatment for 
the first postoperative week, including agents effective 
against gram-negative bacteria, after which this ther-
apy is stopped. 
The other vitally important step in reducing homo-
graft sepsis has been to use biliary reconstructive 
.... 
techniques that prevent systematic contamination by 
gastrointestinal contents (see Fig. 3B, C, and D). 
INDICATIONS FOR LIVER REPLACEMENT 
The understanding of regional hepatic gangrene 
that evolved illustrates well the learning process of 
caring for patients receiving a new kind of treatment. 
With the acquisition of experience, other important 
issues have also been clarified, including that of the 
indications for liver replacement. A brief summary of 
our first 93 consecutive recipients, treated from 
March, 1963, to November, 1974, can be used to illus-
trate these indications in the light of the results after 
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a minimal potential follow-up of 14 months.26 The 93 
patients were aged 3 months to 68 years. 
Hepatic Malignancy 
The indication for 15 of these transplants was hepa-
toma, cholangiocarcinoma, intrahepatic duct cell car-
cinoma, or hemangioendothelial sarcoma. Seven of 
these patients died within 39 days from technical 
problems of one kind or other. 
Six patients had more prolonged survival, but died 
after 76, 87, 143,339,400, and 432 days. In a116, me-
tastases were present and in 5, the recurrences were 
directly responsible for death. Two other more re-
cently treated patients who had intrahepatic duct cell 
carcinomas are still alive after 22 and 16 months, but 
the recipient with the longer follow-up has extensive 
metastatic disease. 
An additional unsuspected hepatoma was found in a 
4-year-old child treated for extrahepatic biliary atre-
sia. This child is still alive, now 6 years after the 
operation; she has no evidence of recurrence of neopla-
sia. 
Because of the high rate of recurrent malignancy, it 
has become our policy to consider liver replacement 
for primary liver tumors only under the most excep-
tional circumstances, even though our experience and 
that of Daloze of Montreal and CaIne of Cambridge 
have demonstrated the possibility of an occasional 
tumor cure. 
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Biliary Atresia 
Far more desirable candidates are those without 
neoplasms, in spite of the fact that the technical dif-
ficulties in benign hepatic disease are more severe 
because the patients tend to be sicker and to have 
more advanced portal hypertension. Moreover, if the 
diagnosis is biliary atresia, an increased incidence of 
vascular anomalies can be expected to compound the 
difficulties, together with the small size of the struc-
tures to be anastomosed in these young patients.27 
Nevertheless, the longest survivors of liver transplan-
tation in the world are those who had this disorder 
(Fig. 7). Of our own series of 40 patients with biliary 
atresia, treated 14 months or longer ago, including' the 
child with the incidental hepatoma already men-
, tioned, 11 lived for longer than 1 year and 7 are still 
surviving with completely normal liver function 16 
months to 6 ye\lrs after operation. Three of the late 
deaths after 13, 131/2, and 30 months were from recur-
rent hepatic insufficiency caused in two instances by 
chronic rejection, but probably in the third by indolent 
viral hepatitis. The fourth late death after 41 months 
occurred a few weeks after a bout of Hemophilus sep-
ticemia, which had resulted in multiple organ dam-
age. 
-The potential of liver transplantation for the treat-
ment of biliary atresia will not be realized until the 
heavy early mortality is reduced. A recent analysis of 
the deaths wi thin the - first postoperative year has 
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. Figure 7. The course of a 4-year-old child after orthotopic liver transplantation for the indication of biliary atresia. Note the rejection episodes 
It 1 month and 2'/. months. which were easily controlled. The patient, who died after 3'/. years, was for a long time the longest-surviving liver 
reCipient In the world. This distinction now belongs to another child whose original disease was biliary atresia and who has been followed for 6 
years after transplantation. 
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shown the overwhelming contribution of technical and 
mechanical problems to the acute loss rate. 26 Inability 
to control rejection played a surprisingly minor role. 
With the use of microsurgical techniques and an in-
creased alertness to biliary tract complications, there 
is no reason why these children should not be the best 
of all potential candidates for liver replacement. 
Cirrhosis 
Among the 93 consecutive patients treated with 
liver replacement, there were 18 with cirrhosis due to 
chronic aggressive hepatitis (9 children and 9 adults) 
and 9 with end-stage alcoholic cirrhosis. Six of the 18 
patients with chronic aggressive hepatitis lived for at 
least 1 year. Only 1 of the 9 with alcoholic cirrhosis 
lived into the second postoperative year. 
Undoubtedly, one reason for the bad experience 
with cirrhotic patients has been a reluctance to recom-
mend such therapy except in the agonal stages of the 
disease. Now that the feasibility of long-term survival 
and rehabilitation has been' demonstrated, transplan-
tation at an earlier time probably should be consid-
ered, particularly in cases of postnecrotic cirrhosis in 
which the maximal value of medical management and 
of abstinence from alcohol has already been realized. 
Other Indications 
Periodic reassessment of the influence of the origi-
nal host disease upon the outcome will also be neces-
sary insofar as this factor influences future case 
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TIME IN DAYS 
selection. None of the diseases for which liver 
transplantation has been used so far can be categori. 
cally precluded as an indication for further trial, 
especially in children. The brightest chapter in live; . 
transplantation has been in the treatment of inborn 
errors of metabolism in children, including our two 
cases of Wilson's disease (one patient is alive after 6 
years, the other died after 6 years [Fig. 8]), our patient 
with alpha-I-antitrypsin deficiency (alive after 21, 
years), and Daloze's child with Niemann-Pick disease: 
who is alive after 11/2 years. It has become clear ~t 
the hepatic-based inborn errors of metabolism are aU 
potentially curable with liver transplantation. 
Other conditions for which transplantation has been' 
. p_erformed include congenital biliary cirrhosis pri. 
mary biliary cirrhosis, secondary biliary cirrhosis, 
sclerosing cholangitis, the Budd-Chiari syndrome, and 
a~ute and chronic serum hepatitis due to the HBaAg 
VIrus. 
Even continued efforts to treat recipients with 
chronic HB.Ag antigenemia are probably warranted, 
especially if hyperimmune specific gamma globulin 
therapy can be offered. Without such treatment it 
seems highly probable that the new liver will eve~tu_ 
ally be afflicted. with the same disease that destroYed 
the native organ (Fig. 9). 
Future Prospects 
In a positive sense, the most important conclUSion 
that has emerged from the experience with our first 93 
-- OT 27 II Y.O.d 
24.7 ~ 30.0 kQ. 
TIME IN WEEKS MONTHS 
FIgure ,. Course of a child with Wilson·s disease and hepatic cirrhosis who was treated with liver replacement in July, 1969. He lived for sIx 
years without stigmata of recurrent Wilson's disease. Eventually his death was caused by chronic partial biliary duct obstruction of the homo-
graft, which led to widespread intrahepatic sludge formation. (From DuBois, R. S .• et al.: Lancet. 1:505.1971.) 
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FIgure 9. The course of a patient who was terminally ill with chronic aggressive hepatitiS. Australia (Au) antigen-positive. She was treated by 
liver replacement. Note that a/l serologic evidence of serum hepatitiS disappeared immediately after operation only to return some weeks later. 
AG. agarose gel micro-Ouchterlony test for Au antigen. IEOP. quantitative immunoelectro-osmophoresis test for Au antigen. CF, complement 
fixation test for Au antigen. ACA, anticomplementary activity, which is thought to reflect the presence of circulating antigen-antibody complexes; 
the test is not immunologically specitic for Au antigen. Normal Bessey-Lowry (B-L) units for alkaline phosphatase are less than 3. This patient 
eventually developed a modified serum hepatitiS in her homograft and died 20 months alter transplantation. (From Torisu. M .. et al.: Ann. Surg., 
174:620, 1971.) 
consecutive liver replacements was that prolonged 
survival repeatedly was possible. A total of 27 patients 
lived for at least a year following operation, and 16 of 
this group are still alive after more than 1 to almost 6 
years. The outlook has slowly improved, although not 
to a satisfactory state. The first 25 recipients who 
formed the basis of a monograph on liver transplanta-
tion27 included only 5 one-year survivors. The next 
group of 25 contained 6, and the group from 51 to 75 
had 8 one-year survivors. There have already been 8 
one-year survivors among the 18 patients beginning 
with number 76. 
The chronic survivors, particularly those in recent 
times, have had remarkably stable liver function, and 
usually they have achieved complete social rehabili-
tation. Survival of more than a year after orthotopic 
liver transplantation has been recorded from other 
centers by Williams and CaIne and their associates in 
England,30 by Daloze and his colleagues in Canada," 
. and by Hume and his associates in the United 
States. to 
In our own case material of 93 consecutive cases,26 
rejection of the liver as judged by classical histopatho-
logic criteria played a surprisingly small role in the 
heavy overall mortality, accounting for less than 10 
per cent of the deaths. Technical or mechanical prob-
lems, especially those of biliary duct reconstruction, 
were a far greater cause of failure-, as were systemic 
infections. When abnormalities of liver function devel-
oped in the postoperative period, the nearly ~utomatic 
diagnosis of homograft rejection proved' in retrospect 
to have been wrong in most instances. " , 
Further developme~t of liver transplantation de-
pends upon three kinds of progress. First,' earlier 
decisions for transplantation will be necessary, espe-
cially in adult recipientS. Second, there must ~ reduc-
tion of operative and early postoperativeaecidents and 
complications by more discriminating case selection, 
purely technical improvement, and better standard-
ization of biliary duct reconstruction. The third area 
will be sharpening the criteria for the differential 
diagnosis of postoperative hepatic malfunction. includ-
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ing the liberal use of transhepatic cholangiography 
and needle biopsy. Only then can better decisions be 
made about changes in medication or about the need 
for secondary corrective surgical procedures. 
The frequency with which liver transpIantation is 
being used is steadily increasing. Within the next five 
years, it is virtually certain that this approach to the 
treatment of liver disease will become far more widely 
accepted. 
AUXILIARY LIVER TRANSPLANTATION 
Both in experimental animals and in patients, sur-
vival after auxiliary transplantation has been inferior 
to that with the orthotopic procedure. The reasons for 
these disappointing results have not been entirely 
clear, but plausible explanations have been advanced 
indicting both metabolic and mechanical factors. 
Metabolic Considerations 
When auxiliary liver transplantation was first at-
tempted in immunosuppressed canine recipients, a 
curious and disquieting observation was soon made.21 
The extra organs underwent rapid shrinkage, which 
was usually evident within 2 weeks and which was 
Recipient 
~i~ // 
{; 
• Y. 
of· donor I. v.c. 
Recipient I.Y.c. 
--Aorta 
(limb of Roux-en-y) 
Figure 10. Auxiliary liver transplantation with a technique that 
provides an adequate blood supply for the homograft. Note that the 
transplant is given a double blood supply and that the venous com-
ponent is from the non hepatic splanchnic bed. Biliary drainage can 
be with a Roux-en-Y cholecystojejunostomy. 
very advanced at all times after one month. Sub-
sequent research has shown that the atrophy can be 
prevented if the homograft's portal inflow is provided 
with blood returning from the pancreas. The most im. 
portant constituent of portal venous blood in main-
taining liver health has been demonstrated unequivo-
cally to be insulin. 18. 25 
Clinical Experience 
In most of the early attempts at auxiliary liver 
transplantation, the homograft was not given an ac-
ceptable blood supply by the criteria just deSCribed. 
The results were uniformly poor.1? 
More recently, Fortners has reported survival of 
more than one year in a child with biliary atresia 
whose auxiliary liver was furnished with both an arte-
rial and an adequate splanchnic venous inflow similar 
to that shown in Figure 10. 
This single success has demonstrated the feasibility 
of auxiliary liver transplantation. However, the tech-
nical difficulties of achieving optimal revasculariza-
tion, the abdominal' over-crowding by the addition of 
an extra large organ, and the consequent pUlmonary 
complications that have plagued auxiliary transplant 
recipients have all suggested that the auxiliary proce-
dure will play no more than a minor role in the exploi-
tation of clinical liver transplantation. 
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LUNG TRANSPLANTATION 
Keith Reemtsma, M.D., and Henry M. Spotnitz, M.D. 
HISTORICAL ASPECTS 
Among the various organs, the lung was one of the 
'last to be used in experimental transplantation. De-
rnikhov17 first investigated experimental pulmonary 
transplantation extensively. He developed techniques 
for transplantation of lobes and the intact lung in 
dogs. Metras40 was the first to utilize the atrial cuff 
technique for the venous anastomosis. Juvenelle in 
1951 performed the first successful orthotopic auto-
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